Benzipril plus Amlodipine vs Benzipril plus HCT
http://www.courses.ahc.umn.edu/pharmacy/5822/ACCOMPLISH.pdf
ALLHAT
Antihypertensives and Lipid-Lowering to prevent Heart Attack Trial
http://www.nhlbi.nih.gov/health/allhat/qckref.htm
AFFIRM
Rhythm vs Rate control in Afib
ARBITER 6 HALTS
The randomized trial was designed to compare two distinct treatment strategies—raising HDL cholesterol with niacin or lowering LDL-cholesterol levels with ezetimibe—for the treatment of atherosclerosis in 400 patients with known coronary or vascular disease or coronary risk equivalents. Trial stopped early. Adding extended-release niacin (Niaspan, Abbott) to statin therapy results in a significant regression of atherosclerosis as measured by carotid intima-media thickness (IMT), whereas the addition of ezetimibe (Zetia, Merck/Schering-Plough) to statin therapy did not at eight months and 14 months. Although not powered for clinical outcomes, there were more major cardiovascular events in the ezetimibe arm compared with those in the niacin arm (nine events vs two events, respectively; p=0.04)
http://www.theheart.org/article/1022265.do
ENHANCE
Ezetimibe with simvastatin did not show any increased affect on intimal thickness
JUPITER
(Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Benifit of statin therapy in patients without hyperlipidemia (LDL-C <130 mg/dL) but had elevated high-sensitivity C-reactive protein (≥2 mg/L) patients were assigned to receive placebo or 20-mg rosuvastatin daily and were followed to assess the effects of statin therapy on the first occurrence of major cardiovascular events.
statin therapy reduces the incidence of major cardiovascular events in apparently healthy persons who do not have hyperlipidemia but have elevated high-sensitivity C-reactive protein
The primary endpoints of the study included the first major cardiovascular event (defined as nonfatal myocardial infarction), nonfatal stroke, hospitalization for unstable angina, an arterial revascularization procedure, or confirmed death from cardiovascular causes. Secondary end points included the components of the primary end point considered individually—arterial revascularization or hospitalization for unstable angina, myocardial infarction, stroke, or death from cardiovascular causes—and death from any cause. This study demonstrated that persons with LDL-C <130 mg/dL, but with elevated hs-CRP >2 mg/L, had a significant benefit from statin therapy. Rosuvastatin (20 mg) decreased all primary endpoints, including rates of myocardial infarction, stroke, revascularization, hospitalization for unstable angina, and death from all cardiovascular causes. Of the individuals enrolled in this study, 41% were also defined as having metabolic syndrome, thereby demonstrating the primary preventive effect on this population of patients.
JUPITER
(Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Benifit of statin therapy in patients without hyperlipidemia (LDL-C <130 mg/dL) but had elevated high-sensitivity C-reactive protein (≥2 mg/L) patients were assigned to receive placebo or 20-mg rosuvastatin daily and were followed to assess the effects of statin therapy on the first occurrence of major cardiovascular events.
statin therapy reduces the incidence of major cardiovascular events in apparently healthy persons who do not have hyperlipidemia but have elevated high-sensitivity C-reactive protein
The primary endpoints of the study included the first major cardiovascular event (defined as nonfatal myocardial infarction), nonfatal stroke, hospitalization for unstable angina, an arterial revascularization procedure, or confirmed death from cardiovascular causes. Secondary end points included the components of the primary end point considered individually—arterial revascularization or hospitalization for unstable angina, myocardial infarction, stroke, or death from cardiovascular causes—and death from any cause. This study demonstrated that persons with LDL-C <130 mg/dL, but with elevated hs-CRP >2 mg/L, had a significant benefit from statin therapy. Rosuvastatin (20 mg) decreased all primary endpoints, including rates of myocardial infarction, stroke, revascularization, hospitalization for unstable angina, and death from all cardiovascular causes. Of the individuals enrolled in this study, 41% were also defined as having metabolic syndrome, thereby demonstrating the primary preventive effect on this population of patients.
PLATO STEMI 2009
The investigational antiplatelet agent ticagrelor (AstraZeneca) was superior toclopidogrel in a subset of almost 8500 patients with ST-segment-elevation MI (STEMI) undergoing planned PCI in the Platelet Inhibition and Patient Outcomes (PLATO) trial. The results of this predefined subanalysis of PLATO were reported during a late-breaking clinical-trial session here at the American Heart Association 2009 Scientific Sessions and echoed the overall findings of PLATO as reported at the European Society of Cardiology meeting in Barcelona in the summer.
Clinical Trials Summary page
